Collaborative Research -
Genetic Variation in the NF kappaB Pathway and Ovarian Cancer Etiology The aim of this study is to investigate the role that genetic variation in the NF-kappaB pathway plays in ovarian cancer etiology. This study utilizes a multi-stage design, featuring four independent study populations. -
Genetic Linkage in Colorectal Cancer Families The aim of this study is to identify novel colorectal cancer susceptibility loci using families collected via the Colon Cancer Cooperative Family Registry, an NCI-supported consortium. Genome-wide analysis will be performed followed by fine-mapping on approximately 500 multiply-affected families. -
Pharmacogenetics of Phase II Drug Metabolizing Enzymes – Statistical Pharmacogenomics – Future Studies 1, 2, & 3 The major goals of this project are to investigate the genomic structures of phase-II drug metabolizing enzymes and the pharmacogenetics of major depression and breast cancer treatment. -
Inherited Variations in Drug Metabolizing Enzymes The goal of this study is to explore of the role of inheritance in individual variation in methyl conjugation focusing our efforts on a small number of selected MT enzymes of medical significance, but also to expand those studies to include the “pathway” required to generate S-adenosyl-L-methionine (AdoMet), the methyl donor for most small molecule MTs. -
Pharmacogenomics of cytosine arabinoside (Ara-C) and acute myelogenous leukemia Cytosine arabinoside (Ara-C) is the single most effective drug used in the treatment of acute myelogenous leukemia (AML). However, Ara-C efficacy and toxicity vary widely among patients with this disease. Therefore, we propose to study the pharmacogenomics of Ara-C. The results of these studies will increase our understanding of the contribution of inheritance to individual variation in Ara-C efficacy and toxicity, and will help us to move toward the goal of “individualized” therapy with this important antineoplastic drug used in the treatment of AML. -
Inflammation-related genes as risk factors for pancreatic cancer The objective of this K12 proposal is to identify potential disease-susceptibility genes, focusing on inflammation-related genes, in patients with pancreatic ductal adenocarcinoma compared to healthy controls. We also want to determine how polymorphisms of inflammation-related genes interact with environmental factors, namely, smoking and nonsteroidal anti-inflammatory drugs (NSAIDs). In addition we will examine how the presence of polymorphisms in pancreatic cancer patients affects their survival after surgical resection.
|
